HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.

Abstract
To estimate the threshold of nigrostriatal dysfunction required for symptomatic Parkinson's disease (PD), we employed [11C]RTI-32 and PET to study the dopamine transporter in striatal subdivisions of 11 L-dopa-naive patients with very early parkinsonism. As compared with the controls (N = 10), the PD group had on the side contralateral to the maximal clinical symptoms, significantly reduced binding in the posterior putamen (-56%) and anterior putamen (-28%), with the reduction in caudate (-12%) not significantly different. To the extent that dopamine transporter binding accurately reflects the number of nigrostriatal dopamine nerve terminals, these findings suggest that the clinical threshold for PD in the middle-age human is approximately 50% loss of dopaminergic innervation to the posterior putamen. Our data also suggest that damage to the putamen component of the striatum is sufficient for the clinical expression of PD.
AuthorsM Guttman, J Burkholder, S J Kish, D Hussey, A Wilson, J DaSilva, S Houle
JournalNeurology (Neurology) Vol. 48 Issue 6 Pg. 1578-83 (Jun 1997) ISSN: 0028-3878 [Print] United States
PMID9191769 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carbon Radioisotopes
  • Carrier Proteins
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
Topics
  • Adult
  • Carbon Radioisotopes
  • Carrier Proteins (analysis)
  • Disease Progression
  • Dopamine Plasma Membrane Transport Proteins
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Middle Aged
  • Nerve Tissue Proteins (analysis)
  • Parkinson Disease (diagnostic imaging, metabolism, physiopathology)
  • Substantia Nigra (chemistry, physiopathology)
  • Time Factors
  • Tomography, Emission-Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: